Abstract

7056 Background: Vincristine is associated with CIPN that can impair daily function. Methods: Patients 3.0-9.9 years without neurological disorders, enrolled on ALL0932 at 26 sites, were evaluated ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches
Robert Knoerl ... Donna L Berry
Patient Education and Counseling | VOL. 102
Robert Knoerl, et. al.Robert Knoerl ... Donna L Berry
09 Apr 2019
Exploring Clinicians' Perspectives of Barriers to Chemotherapy-Induced Peripheral Neuropathy Assessment and Management in Oncology Practice: A Qualitative Analysis of Semi-structured Interviews.
Robert Knoerl ... Donna L Berry
CANCER NURSING&trade | VOL. 46
Robert Knoerl, et. al.Robert Knoerl ... Donna L Berry
14 Mar 2022
Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences.
Alice Yu ... Eva Battaglini
Supportive Care Cancer | VOL. 29
Alice Yu, et. al.Alice Yu ... Eva Battaglini
22 Apr 2021
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
Kelly W Maloney ...
Journal of Clinical Oncology | VOL. 38
Kelly W Maloney, et. al.Kelly W Maloney ...
11 Dec 2019
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Yoon-Koo Kang ... Sung Hoon Noh
Journal of Clinical Oncology | VOL. -
Yoon-Koo Kang, et. al.Yoon-Koo Kang ... Sung Hoon Noh
12 Jul 2024
Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
Laura E G Warren ... Jennifer R Bellon
Journal of Clinical Oncology | VOL. -
Laura E G Warren, et. al.Laura E G Warren ... Jennifer R Bellon
11 Jul 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
Aoba Okeya ... Chikako Shimizu
Journal of Clinical Oncology | VOL. -
Aoba Okeya, et. al.Aoba Okeya ... Chikako Shimizu
11 Jul 2024
Reply to A. Okeya et al.
Miguel Martín ... Joohyuk Sohn
Journal of Clinical Oncology | VOL. -
Miguel Martín, et. al.Miguel Martín ... Joohyuk Sohn
11 Jul 2024
View more papers